본문 바로가기
KERD
논문KCI 등재

The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty

오연정|황일태|양원준|고근혁|이곤희
대한소아내분비학회 (Korean Society Of Pediatric Endocrinology)|2017.03|Annals of Pediatric Endocrinology & Metabolism|제22권 제1호|pp. 49-54|DOI http://doi.org/10.6065/apem.2017.22.1.49

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

ObesityOverweightBody mass indexCentral precocious pubertyGonadotropin-releasing hormone agonist
주제분류소아과학

초록

Purpose: The effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on body mass index (BMI) are controversial in girls with central precocious puberty (CPP). We therefore evaluated auxological parameters during GnRHa therapy in patients with CPP, specifically focusing on changes in BMI. Methods: Seventy-seven girls with idiopathic CPP who underwent GnRHa therapy were retrospectively recruited. We investigated BMI changes during the treatment period after stratifying them according to baseline BMI status as follows: normal (BMI percentile of <85th) and overweight groups (BMI percentile of ≥85th). Results: The incidence of overweight/obesity (40.3%/23.4%) was very high in the girls with CPP. In the overall study population, no significant BMI change was observed during the GnRHa treatment period. However, when stratified according to baseline BMI status, the normal-weight group showed a significant increase in BMI-standard deviation score (SDS), whereas the overweight group showed no change in BMI-SDS. Baseline BMI-SDS was an independent predictor of changes in BMI during the GnRHa treatment period. Changes in weight-SDS were similar, but changes in height-SDS were significantly greater in the overweight group than in the normal-weight group, which explains the observed difference in BMI-SDS. Conclusion: Our results demonstrate that the difference in the pattern of BMI changes among our CPP patients suggests that delayed puberty induced by GnRHa treatment may have different effects on linear growth according to baseline body composition. This study underscores the importance of individualized lifestyle intervention in CPP children.

Abstract

Purpose: The effects of gonadotropin-releasing hormone agonist (GnRHa) treatment on body mass index (BMI) are controversial in girls with central precocious puberty (CPP). We therefore evaluated auxological parameters during GnRHa therapy in patients with CPP, specifically focusing on changes in BMI. Methods: Seventy-seven girls with idiopathic CPP who underwent GnRHa therapy were retrospectively recruited. We investigated BMI changes during the treatment period after stratifying them according to baseline BMI status as follows: normal (BMI percentile of <85th) and overweight groups (BMI percentile of ≥85th). Results: The incidence of overweight/obesity (40.3%/23.4%) was very high in the girls with CPP. In the overall study population, no significant BMI change was observed during the GnRHa treatment period. However, when stratified according to baseline BMI status, the normal-weight group showed a significant increase in BMI-standard deviation score (SDS), whereas the overweight group showed no change in BMI-SDS. Baseline BMI-SDS was an independent predictor of changes in BMI during the GnRHa treatment period. Changes in weight-SDS were similar, but changes in height-SDS were significantly greater in the overweight group than in the normal-weight group, which explains the observed difference in BMI-SDS. Conclusion: Our results demonstrate that the difference in the pattern of BMI changes among our CPP patients suggests that delayed puberty induced by GnRHa treatment may have different effects on linear growth according to baseline body composition. This study underscores the importance of individualized lifestyle intervention in CPP children.

참고문헌 (32)

  1. Carel JC, "Consensus statement on the use of gonadotropin-releasing hormone analogs in children", Pediatrics, 123, pp.e752~e762 (2009)
  2. Crowley WF Jr, "Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty", J Clin Endocrinol Metab, 52, pp.370~372 (1981)
  3. Breyer P, "Gonadotropin-releasing hormone agonists in the treatment of girls with central precocious puberty", Clin Obstet Gynecol, 36(764), pp.764~772 (1993)
  4. Carel JC, "Precocious puberty and statural growth", Hum Reprod Update, 10, pp.135~147 (2004)
  5. Kauli R, "Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method", Horm Res, 47, pp.54~61 (1997)
  6. Wang Y, "Worldwide trends in childhood overweight and obesity", Int J Pediatr Obes, 1, pp.11~25 (2006)
  7. Dunger DB, "Effects of obesity on growth and puberty", Best Pract Res Clin Endocrinol Metab, 19, pp.375~390 (2005)
  8. Chiumello G, "Precocious puberty and body composition: effects of GnRH analog treatment", J Pediatr Endocrinol Metab, 13(Suppl), pp.791~794 (2000)
  9. Currie C, "Is obesity at individual and national level associated with lower age at menarche? Evidence from 34 countries in the Health Behaviour in School-aged Children Study", J Adolesc Health, 50, pp.621~626 (2012)
  10. Pasquino AM, "Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropinreleasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function", J Clin Endocrinol Metab, 93, pp.190~195 (2008)
  11. Arrigo T, "Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty", Eur J Endocrinol, 141, pp.140~144 (1999)
  12. Traggiai C, "Outcome after depot gonadotrophinreleasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height", Eur J Endocrinol, 153, pp.463~464 (2005)
  13. Palmert MR, "Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty", J Clin Endocrinol Metab, 84, pp.4480~4488 (1999)
  14. 이승재, "Effects of Gonadotropin-Releasing Hormone Agonist Therapy on Body Mass Index and Height in Girls with Central Precocious Puberty", 전남의대학술지, 48(1), pp.27~31 (2012), 의과학연구소
  15. Aguiar AL, "Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues", J Pediatr Endocrinol Metab, 19, pp.1327~1334 (2006)
  16. Shiasi Arani K, "Gonadotropin-releasing hormone agonist therapy and obesity in girls", Int J Endocrinol Metab, 13, pp.e23085~ (2015)
  17. Magiakou MA, "The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study", J Clin Endocrinol Metab, 95, pp.109~117 (2010)
  18. Głab E, "Influence of GnRH analog therapy on body mass in central precocious puberty", Pediatr Endocrinol Diabetes Metab, 15, pp.7~11 (2009)
  19. Arrigo T, "Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty", Eur J Endocrinol, 150, pp.533~537 (2004)
  20. van der Sluis IM, "Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy", J Clin Endocrinol Metab, 87, pp.506~512 (2002)
  21. Wolters B, "Treatment with gonadotropinreleasing hormone analogues: different impact on body weight in normal-weight and overweight children", Horm Res Paediatr, 78, pp.304~311 (2012)
  22. Bayley N, "Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards", J Pediatr, 40, pp.423~441 (1952)
  23. Reilly JJ, "Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review", Int J Obes (Lond), 35, pp.891~898 (2011)
  24. 오경원, "한국 소아청소년의 비만 유병률 추이: 1997년과 2005년 비교", Korean Journal of Pediatrics, 51(9), pp.950~955 (2008), 대한소아과학회
  25. Willemsen RH, "Pros and cons of GnRHa treatment for early puberty in girls", Nat Rev Endo, 10, pp.352~363 (2014)
  26. De Leonibus C, "Update on statural growth and pubertal development in obese children", Pediatr Rep, 4, pp.e35~ (2012)
  27. Müller J, "Hormonal changes during GnRH analogue therapy in children with central precocious puberty", J Pediatr Endocrinol Metab, 13(Suppl 1), pp.739~746 (2000)
  28. Oostdijk W, "Final height in central precocious puberty after long term treatment with a slow release GnRH agonist", Arch Dis Child, 75, pp.292~297 (1996)
  29. Antoniazzi F, "Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation", J Clin Endocrinol Metab, 88, pp.1096~1101 (2003)
  30. Ko JH, "Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist", Horm Res Paediatr, 75, pp.174~179 (2011)
  31. Messaaoui A, "Treatment of central precocious puberty with Gonadotropin- Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment", Rev Med Brux, 26, pp.27~32 (2005)
  32. "J Clin Epidemiol", 2006, 920~925

관련 논문AI추천

The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty구재균, 김나리, 김성우, 김영배, 김은정, 이원경, 이정은, 정선희, 정우영대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2017 · 제22권 제2호Longitudinal follow-up to near final height of auxological changes in girls with idiopathic central precocious puberty treated with gonadotropin- releasing hormone analog and grouped by pretreatment body mass index level김용대, 박종호, 한헌석, 황태호대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2018 · 제23권 제1호Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty김혜련, 남효경, 이기형, 이영준대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2017 · 제22권 제4호Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapyHwang Jin Soon, Lee Hae Sang, Lim Kyung In대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2020 · 제25권 제3호Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty김재현, 박진아대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2017 · 제22권 제1호Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoateAroonparkmongkol Suphab, Chatdamrongsakool Krittamate, Numsriskulrat Nattakarn, Srilanchakon Khomsak, Supornsilchai Vichit, Thaneetrakool Thanaporn, Wacharasindhu Suttipong대한소아내분비학회 · Annals of Pediatric Endocrinology & Metabolism2025 · 제30권 제4호

이 간행물의 다른 논문 (10건)

Bone modeling, remodeling, and skeletal health in children and adolescents: mineral accrual, assessment and treatmentChiara Maggioli, Stefano Stagipp. 1-5Perfluoroalkyl substances exposure and thyroid hormones in humans: epidemiological observations and implications이정은, 최경호pp. 6-14Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes이승아, 이동윤pp. 15-26Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty김재현, 박진아pp. 27-35Influence of The -202 A/C insulin-like growth factorbinding protein-3 promoter polymorphism on individual variation in height in Korean girl이민주, 박태영, 양승, 황일태pp. 36-42
원문 보기